ReviewSclerotherapy for low-flow vascular malformations of the head and neck: A systematic review of sclerosing agents☆
Introduction
Vascular malformations are congenital lesions of the vascular or lymphatic system, which occur due to an erroneous vascular development during embryogenesis. These abnormal dilated vessels grow proportionally to body size and do not usually show spontaneous regression. Since 1996, the International Society for the Study of Vascular Anomalies (ISSVA) has been providing an up-to-date classification system for vascular anomalies, in which a clear distinction between vascular tumors (such as the common infantile hemangioma) and malformations is made.1 Vascular malformations can be divided into high- and low-flow malformations: arteriovenous malformations (AVMs) are high flow due to the arterial blood flow pattern; capillary (CMs), lymphatic (LMs), and venous malformations (VMs) are low-flow lesions.
The greatest proportion of low-flow malformations is located in the head and neck region.2 A multidisciplinary treatment, which involves consultation of various head and neck specialists, such as plastic surgeons, ophthalmologists, craniofacial surgeons and otolaryngologists, is often required.
In general, CMs are superficial and do not usually cause mass effect. Cutaneous CMs, also known as port-wine stains, are therefore mostly treated with laser therapy.3 For LMs and VMs, surgical excision was traditionally the treatment of choice.4 However, due to infiltration and expansion of the lesion in adjacent anatomical structures, surgery is not always a feasible treatment option and may lead to severe complications such as nerve damage. For these reasons, many experts currently consider sclerotherapy as the first-line therapy for LMs and VMs, sometimes in combination with surgical debulking. In sclerotherapy, intralesional injections with sclerosing agents damage the endothelium followed by inflammation, thrombotic vascular occlusion, and sclerosis, with regression of the vascular malformation as the intended result.5
To date, a wide range of sclerosing agents have been used in daily practice, but it is unclear which sclerosing agent is superior in terms of safety and effectiveness.6, 7 The goal of this systematic review is to investigate and compare the effectiveness and safety of the most frequently used sclerosing agents for LMs and VMs of the head and neck. With a systematic review, we aim to aid physicians in evidence-based therapeutic decision making.
Section snippets
Methods
We followed the guidelines of the PRISMA statement 2009 for this systematic review.8
Results
The search revealed 1155 articles, of which 36 fulfilled our inclusion criteria (Figure 1).
The most frequently reported sclerosing agents, sorted from highest to lowest patient number, were pingyangmycin (PYM), absolute ethanol, OK-432 (picibanil), ethanolamine oleate, bleomycin, polidocanol, doxycycline, and STS. All articles were rated as low or very low evidence, mainly due to retrospective study designs and small patient groups. Study characteristics and outcomes of the included studies per
Discussion
Our data suggest that all sclerosing agents are effective when used in LMs, VMs, or both, with a mean complete response varying from 39% to 79% and an excellent overall response between 71% and 100%. Ethanol and STS were exclusively used for the treatment of VMs and doxycycline and OK-432 for LMs, while the remaining sclerosing agents were used in both types of malformation. A complete response was least often observed in patients treated with OK-432 and bleomycin. However, the small patient
Conclusion
This systematic review failed to identify the “optimal” sclerotherapy. All sclerosing agents seem to be effective, but we were not able to compare these agents in a meta-analysis due to the lack of high-quality controlled studies. However, until stronger evidence is available, the difference in complication rates is potentially the deciding factor in the choice between sclerosing agents. As absolute ethanol leads to a high complication rate and severe local complications, plastic surgeons and
Conflict of interest statement
None.
Financial disclosure
The authors have no relevant financial relationships to disclose.
Acknowledgments
None.
References (54)
- et al.
ISSVA classification
Semin Pediatr Surg
(2014) - et al.
Vascular anomalies: what they are, how to diagnose them, and how to treat them
Curr Probl Diagn Radiol
(2011) - et al.
Percutaneous sclerotherapy for vascular malformations: a systematic review
Ann Vasc Surg
(2014) - et al.
Sclerotherapy of microcystic lymphatic malformations in oral and facial regions
J Oral Maxillofac Surg
(2009) - et al.
A clinical study of ultrasound-guided intralesional injection of bleomycin A5 on venous malformation in cervical-facial region in China
J Vasc Surg
(2010) - et al.
Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations
J Vasc Surg
(2011) - et al.
Sclerotherapy of oral and facial venous malformations with use of pingyangmycin and/or sodium morrhuate
Int J Oral Maxillofac Surg
(2004) - et al.
Intralesional injection of pingyangmycin for vascular malformations in oral and maxillofacial regions: an evaluation of 297 consecutive patients
Oral Oncol
(2009) - et al.
The role of intralesional pingyangmycin in the treatment of venous malformation of facial and maxillary region
Int J Pediatr Otorhinolaryngol
(2008) - et al.
Treatment of venous malformations: first experience with a new sclerosing agent–a multicenter study
Eur J Radiol
(2011)
Absolute ethanol sclerotherapy for venous malformations in the face and neck
J Oral Maxillofac Surg
OK-432 therapy for lymphangioma in children: why and how does it work?
J Pediatr Surg
Treatment of lymphatic malformations: a more conservative approach
J Pediatr Surg
Sclerotherapy for congenital lesions in the head and neck
Otolaryngol Head Neck Surg
Bleomycin sclerotherapy in congenital lymphatic and vascular malformations of head and neck
Int J Pediatr Otorhinolaryngol
Comparison between absolute ethanol and bleomycin for the treatment of venous malformation in children
Exp Ther Med
Treatment of low-flow vascular malformations by ultrasound-guided sclerotherapy with polidocanol foam: 24 cases and literature review
Eur J Vasc Endovasc Surg
Sclerotherapy of face and oral cavity low flow vascular malformations: our experience
Br J Oral Maxillofac Surg
Doxycycline sclerotherapy as primary treatment of head and neck lymphatic malformations in children
J Pediatr Surg
Sodium tetradecyl sulphate sclerotherapy for treating venous malformations of the oral and pharyngeal regions in children
Int J Pediatr Otorhinolaryngol
Laser treatment of port-wine stains
Clin Cosmet Investig Dermatol
Cystic hygroma
Lancet
Sclerotherapy of lymphangiomas of the head and neck
Head Neck
Effectiveness of sclerotherapy, surgery, and laser therapy in patients with venous malformations: a systematic review
Cardiovasc Interv Radiol
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
BMJ
A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis
BMJ
Pingyangmycin as first-line treatment for low-flow orbital or periorbital venous malformations: evaluation of 33 consecutive patients
JAMA Ophthalmol
Cited by (155)
Intralesional injection of bleomycin in the management of low flow vascular malformations: Results and factors affecting the outcome
2024, Journal of Vascular Surgery: Venous and Lymphatic DisordersIntrabursal Doxycycline Sclerotherapy for Recurrent Olecranon Bursitis of the Elbow: A Case Control Study
2024, Journal of Hand Surgery Global OnlineStudy of vascular sclerosing agent based on the dual mechanism of vascular endothelial cell damage-plasmin system inhibition
2023, Biochemical and Biophysical Research CommunicationsThe efficacy of bleomycin sclerotherapy in the treatment of lymphatic malformations: a review and meta-analysis
2023, Brazilian Journal of OtorhinolaryngologyEfficacy and safety of foam sclerotherapy with sodium tetradecyl sulfate as preferred sclerosant of venous malformations based on experience from a single specialist center
2023, Journal of Vascular Surgery: Venous and Lymphatic DisordersCitation Excerpt :This was evident in our study, in which the patients had received ∼1.6 sclerotherapy sessions (range, 1-6) within 5 years. Despite the success of sclerotherapy, a systematic review by Horbach et al24 demonstrated no clear evidence regarding which agent is the safest and most effective. The patients who had required multiple sclerotherapy sessions were distributed among the Puig types: type I, n = 7 (20.6%); type II, n = 38 (34.2%); type III, n = 28 (45.9%); and type IV, n = 1 (100%).
Effectiveness and safety of percutaneous sclerotherapy using absolute ethanol and/or polidocanol for maxillofacial venous malformations involving the masticatory muscles: A case series
2023, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- ☆
Part of this manuscript was presented at the annual conference of the Dutch ophthalmology association (Nederlands Oogheelkundig Gezelschap), March 25th–27th 2015.
- d
These authors contributed equally to this paper.